Evidence map›Paper›PMID 42307918›Full record

Trial reportJAMA psychiatry2026

Gastrointestinal Interoception and Relapse in Anorexia Nervosa.

Charles Verdonk, Keller Mink, Emily Choquette, Scott E Moseman, Ahmad Mayeli, Jennifer L Stewart, Martin P Paulus, Ryan Smith, Sahib S Khalsa

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in JAMA psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05111977 (A Neurocomputational Assay of Gastrointestinal Interoception in Anorexia Nervosa), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05111977 naunknown statusnot on this map

A Neurocomputational Assay of Gastrointestinal Interoception in Anorexia Nervosa

TypeinterventionalSponsorLaureate Institute for Brain Research, Inc.Ran2021 to 2026Enrolled150ConditionsAnorexia NervosaArmsVibrant capsule
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Charles VerdonkLaureate Institute for Brain Research, Tulsa, Oklahoma.
Keller MinkLaureate Institute for Brain Research, Tulsa, Oklahoma.
Emily ChoquetteLaureate Institute for Brain Research, Tulsa, Oklahoma.
Scott E MosemanLaureate Eating Disorders Program, Tulsa, Oklahoma.
Ahmad MayeliUniversity of Pittsburgh, Pittsburgh, Pennsylvania.
Jennifer L StewartLaureate Institute for Brain Research, Tulsa, Oklahoma.
Martin P PaulusLaureate Institute for Brain Research, Tulsa, Oklahoma.
Ryan SmithLaureate Institute for Brain Research, Tulsa, Oklahoma.
Sahib S KhalsaLaureate Institute for Brain Research, Tulsa, Oklahoma.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Anorexia nervosa (AN) is a deadly psychiatric disorder with relapse rates approaching 50% after weight restoration. Disrupted gastrointestinal interoception may underlie persistent symptoms and relapse vulnerability. Objective: To examine behavioral, computational, neural, and physiological markers of gastrointestinal interoception in weight-restored individuals with AN and test their association with relapse. Design, Setting, and Participants: This crossover trial was a single-blind, within-participant, randomized (block-order) trial conducted at the Laureate Institute for Brain Research between August 2021 and February 2025. Participants were females with weight-restored restrictive AN and age- and sex-matched healthy comparators (HCs). All participants ingested a vibrating capsule that delivered counterbalanced blocks of normal- and enhanced-intensity gut stimulation. Behavioral detection performance, electroencephalography, peripheral physiology, and computational modeling were used to assess interoception. Main Outcomes and Measures: Experimental-session measures included interoceptive accuracy, prior beliefs, interoceptive precision, learning rates, gastric-evoked potentials (GEPs), and hunger. Main clinical outcomes at 6 months included relapse status and symptom severity. Results: The cohort included 62 female participants with weight-restored restrictive AN (mean [SD] age, 18.9 [4.5] years) and 57 age- and sex-matched healthy comparators (HCs; mean [SD] age, 20.7 [5.3] years). Six-month follow-up data were collected for 54 participants with AN. Compared with HCs, participants with AN showed lower perceptual accuracy (Cohen d = -0.98; 95% CI, -1.51 to -0.44; P = .001) and higher miss rates (Cohen d = 1.02; 95% CI, 0.55 to 1.48; P < .001). Computational modeling revealed in the AN group stronger prior expectations that capsule vibrations would not be present (Cohen d = -0.31; 95% CI, -0.67 to 0.05; P = .05), greater shifts in interoceptive precision between blocks (Cohen d = 0.38; 95% CI, 0.02 to 0.75; P = .01), and learning asymmetries (vibration: Cohen d = -0.40; 95% CI, -0.77 to -0.04; P = .007; no-vibration: Cohen d = 0.35; 95% CI, -0.02 to 0.71; P = .01). GEP amplitudes did not differ by group but were correlated with accuracy and learning in AN. Capsule stimulation induced greater hunger increases in AN (interaction: η2p = 0.04, P = .04; AN: Cohen d = 0.94; 95% CI, 0.57 to 1.30; HCs: Cohen d = 0.40; 95% CI, 0.03 to 0.77). At follow-up, relapse was predicted by initial priors (odds ratio [OR], 3.82; 95% CI, 1.02 to 15.91; P = .05), response bias (OR, 5.37; 95% CI, 1.15 to 32.04; P = .04), and stomach unpleasantness (OR, 5.73; 95% CI, 1.38 to 33.5; P = .03), while eating disorder symptom severity was predicted by miss rate (β = 1.05; R2 = 0.08; P = .05), difference in interoceptive precision (β = 5.84; R2 = 0.16; P = .004), and initial priors (β = -2.99; R2 = 0.09; P = .05). Conclusions and Relevance: In this study of weight-restored females with AN, gastrointestinal interoception was disrupted across multiple domains, including reduced accuracy detecting gut signals, maladaptive priors, rigid learning, and abnormal hunger rating. Several interoceptive markers predicted relapse and symptom severity at follow-up. These findings support the use of ingestible mechanosensory probes and computational modeling as scalable tools to monitor treatment response and guide relapse prevention in eating disorders. Trial Registration: ClinicalTrials.gov Identifier: NCT05111977.

Indexed as

Anorexia NervosaInteroceptionAdolescentAdultCross-Over StudiesElectroencephalographyFemaleHumansHungerRecurrenceSingle-Blind MethodYoung Adult

Identifiers

PMID42307918
PMCPMC13276667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.